FOLFOX plus cetuximab in first-line therapy of advanced colorectal cancer

Roland Ehrenberg, Niels Halama

National Center for Tumor Diseases, Department of Medical Oncology, University Hospital Heidelberg, Heidelberg, Germany

Correspondence to: Niels Halama. National Center for Tumor Diseases, Department of Medical Oncology, University Hospital Heidelberg, Im Neuenheimer Feld 460, Heidelberg, Germany. Email: Niels.Halama@nct-heidelberg.de.


doi: 10.21037/atm.2018.11.22

View this article at: http://dx.doi.org/10.21037/atm.2018.11.22

Oxaliplatinum is derivate of platinum, which has been used for colorectal cancer since 1997 in France for first-line therapy of metastatic colorectal cancer. Following the data from the MOSAIC trial (1), oxaliplatinum-based adjuvant therapy was established. Development of the oxaliplatinum-based protocols lead to the development of FOLFOX4 (2) and FOLFOX6 (3) and subsequent FOLFOX7 protocols (4). Oral formulations of 5-FU as capecitabine (Xeloda) were tested and showed non-inferiority to infusional regimens (5,6) also in second line settings (7) and in combination with oxaliplatinum. The TRIBE trial compared FOLFOXIRI plus bevacizumab vs. FOLFIRI plus bevacizumab (8) where FOLFOXIRI plus bevacizumab yielded a median overall survival (OS) 29.8 months with a benefit of bevacizumab across all analyzed mutational profiles. In contrast, the PRIME trial (9) used prospective analysis of the KRAS status and half of the patients received additionally panitumumab (combination arm), whereas all received FOLFOX4. In this trial of previously untreated colorectal cancer patients, 593 patients were in arm 1 (combination) and 590 in arm 2 (with only FOLFOX4 treatment). In 93% was KRAS status analyzed. Final analyses showed a median progression-free survival (PFS) with panitumumab of 10.0 months versus 8.6 months without. No difference in OS was noted, but there was a clear—but not statistically significant—difference of 23.9 versus 19.7 months observed. The response rates were significant with 57% versus 48%. Patients with KRAS mutation had reduced PFS and OS in combination with panitumumab, whereas KRAS wildtype showed better survival (25.8 versus 20.7 months). In this cohort, further analyses showed ECOG 0/1 patients to benefit most from combination therapy, in the KRAS wildtype cohort. The PEAK trial compared FOLFOX plus panitumumab versus FOLFOX plus bevacizumab in first-line therapy and revealed the combination with panitumumab to be better for KRAS wildtype patients 13.0 versus 9.5 months median PFS, P=0.029 (10). Analysis of the data from the OPUS trial (11) showed for the FOLFOX plus cetuximab combination detrimental outcomes for patients with tumors with KRAS mutations [i.e., worse PFS and objective response rate (ORR)]. In the wildtype population the median PFS was 12.0 versus 5.8 months, only with a trend for significance (P=0.0615). The median OS was 19.8 versus 17.8 months (P=0.8). The described trials therefore have not fully clarified the role of FOLFOX plus cetuximab in first line therapy of colorectal cancer patients with wildtype RAS status. In this situation, the data from the TAILOR study try to close the gap. The TAILOR trial is an open-label, randomized, phase III trial in patients from China comparing FOLFOX-4 with or without cetuximab in RAS wildtype metastatic colorectal cancer. For mutational status, KRAS/NRAS, exons 2 to 4 were investigated, allowing to assess the majority of presenting RAS mutations in patients. The primary endpoint of the TAILOR trial was progression-free survival time; secondary end points included OS time, overall response rate as well as safety and tolerability. In the modified intent-to-treat (mITT) population of a set of 393 patients with RAS wildtype, addition of cetuximab to FOLFOX-4 significantly improved the primary end
point of progression-free survival time compared with FOLFOX-4 alone. Hazard ratio was 0.69 with a 95% confidence interval (CI) of 0.54 to 0.89, \( P=0.004 \), revealing a median PFS of 9.2 versus 7.4 months. The secondary end point of OS time was assessed after 300 events and a hazard ratio of 0.76 was observed (95% CI: 0.61–0.96, \( P=0.02 \)), resulting in a median OS of 20.7 versus 17.8 months. The overall response rate was also significantly different between the two arms (with an odds ratio of 2.41 and a 95% CI: 1.61–3.61, \( P=0.001 \)): 61.1% versus 39.5% respectively. The treatment was well tolerated and no new or unexpected safety issues were observed. The authors report that their inclusion criteria were changed from patients with KRAS exon 2 analyses to patients with extended RAS analysis (KRAS/NRAS exons 2 to 4) being performed on their tumors. The final analysis was based on this mITT population. This might explain the observed differences in OS in this Chinese patient cohort. A total of 20.7 months OS seems to be quite short in comparison to published data [e.g., FIRE-3 data, Heinemann et al. (12), Lancet Oncology] with over 30 months survival. The authors explain this obvious difference with the limited access to oncological substances and oncological care for the investigated patient cohort. The possible inclusion of patient with a RAS/RAF mutational profile beyond the analyzed exon 2 mutations in the initial phase of the trial could further skew the data in an unfavorable manner. Without a retrospective analysis of the included patients, this question cannot be answered. Another aspect that might also contribute to a certain difference between the combination arm and the chemotherapy arm is the balance of metastatic sites in the patients from the two treatment arms. The combination arm has 20.7% with three or more sites of metastases while the chemotherapy only arm has 28.5% of patients with three or more sites involved. Of course, a possibility would be the presentation of volumetric tumor burden for the patients in the trial. Another interesting aspect in comparison to the FIRE-3 data is the sidedness of the primary localization of the tumor. In the TAILOR trial, close 80% of the tumors in the combination arm were located on the left side of the colon. It would be interesting—also in the light of the data from the FIRE-3 trial—to see the sidedness in relation to the treatment outcome in the TAILOR trial population. Another intriguing aspect of the findings observed in the TAILOR trial is the finding, that FOLFOX4 therapy appears to be more beneficial for the BRAF mutant subgroup compared to the combination therapy. This is feeding an ongoing debate, whether or not the addition of EGFR-targeted agents is helpful for BRAF mutated colorectal cancer. Two meta-analyses came to differing conclusions [Rowland et al. (13) versus Pietrantonio et al. (14)]: one concluded that there is insufficient evidence to justify withholding anti-EGFR therapy, the other discouraged the use of anti-EGFR in these patients. More analyses in this direction are clearly needed and currently promising data from the VOLFI trial on the combination of FOLFOXIRI plus panitumumab in BRAF mutated tumors could be reported (15). In terms of toxicities, there were no unexpected findings. Of note, leukopenia and neutropenia in the TAILOR trial were more frequent than reported in previous studies. An explanation for this observation is missing. Apart from this, the TAILOR trial now provides more evidence for the debate around cetuximab plus FOLFOX combinations, corroborating the data from the OPUS trial and setting the ground for acceptable routine use of this combination treatment.

Beyond this, Oxaliplatinum has a long history and is well established in the clinic. Recent data from immunotherapy trials (e.g., NICHE trial, Abstract LBA37_PR ‘Neoadjuvant ipilimumab plus nivolumab in early stage colon cancer’ by Myriam Chalabi, Annals of Oncology, Volume 29 Supplement 8 October 2018) suggest, that it might be more beneficial to apply immunotherapy in earlier stage of the disease. In addition, Oxaliplatinum activity on tumor cells shows immune-stimulating features, most notably immunogenic cell death (16,17) and is also associated with the presence of infiltrating immune cells in the local microenvironment (18). As we see more and more (earlier) immunotherapeutic approaches for microsatellite-stable and microsatellite-instable colorectal cancers in trials, combinatorial approaches are not in the clinic yet. But the presented data suggests the possibility for synergisms and there might be a role for oxaliplatinum-based combination immunotherapies in the future for colorectal cancer.

**Acknowledgements**

None.

**Footnote**

*Conflicts of Interest:* The authors have no conflicts of interest to declare.
References


